A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Exclusion Criteria

• •Pregnant or breastfeeding patients
• •Patients, who suffered from an acute cardiac event within the last 12 months
• •Patients with active vascular disease, either myocardial or peripheral
• •Patients with proliferative and/or vascular retinopathy
• •Patients with known liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune)
• •Patients with known CNS metastatic disease
• •Patients testing positive to one of the following viruses: HIV, HBV or HCV
• •Patients receiving chemotherapy or radiotherapy within the last 4 weeks before enrolment
• •Patients that have undergone major surgery within the last 4 weeks before enrolment
• •Patients may not have received anti-angiogenic therapy within the previous 8 weeks before enrolment.
• •Patients may not have received any other investigational agent within 4 weeks before enrolment.
• •Patients with an ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before enrolment
• •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements